CanSinoBIO ConSino Bio specializes in the development and production of high-qua
With a registered capital of RMB 156 million, ConSinoBio is a national high-tech enterprise founded by the senior management team of a multinational pharmaceutical company. With the mission of providing solutions for the prevention of infectious diseases and infectious diseases worldwide, ConSino Bio specializes in the development and production of high-quality human vaccines.
Immunotherapy in China: A Rising Star in the Field of Cancer Treatment
Immunotherapy is emerging as a powerful weapon in fighting cancer by restarting and maintaining the cancer-immunity cycle to identify, control and eliminate tumor cells rather than killing them directly.
Nov 24, 2022 06:29 PM
CNMPA Approved World's First Inhaled COVID-19 Vaccine Mist
The liquid form of the vaccine is changed into an aerosol using a nebulizer. It can then be inhaled through the mouth using the nebulizer machine. According to CanSino, the vaccine can effectively induce comprehensive immune protection in response to SARS-CoV-2 after just one breath.
Sep 06, 2022 11:48 AM